Neuren Pharma ( NEU.AX) Marketcap: only 48 million A$ Price: 0,34 A$
Awesome Pipeline :
Glypromate MCI in CABG Phase 3 ongoing NNZ-2566 Severe TBI (traumatic brain injury) Phase 2a (deal with US Army) NNZ-2566 Mild/Mod TBI Phase 2 Motiva Post-stroke-Apathy Phase 2b
Taylor Collison http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf
By the end 1Q CY08, we expect Neuren to be running four major efficacy trials; namely three Phase 2 trials for NNZ-2566 in mild/moderate and severe TBI and Motiva™ in post stroke abulia/ depression coupled with the current Phase 3 trial for Glypromate® in CABG. All indications potentially provide Neuren with first to market, billion dollar opportunities. With a current market cap of $40.2m, Neuren remains a solid value proposition in the sector, where FDA INDs for mid to late stage clinical trials continues to remain a vexing proposition. We maintain our Speculative Buy recommendation and price target of $1.30, though expect to make changes to our valuation model once the acquisition has closed, which we expect during the current Q.
ACL Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held